Asian Insight Provider - Actionable ideas, CrossASEAN Research

Henry Soediarko

Asian Insight Provider - Actionable ideas

CrossASEAN Research

At CrossASEAN Research we strive to produce unbiased and differentiated on the ground insights on companies across South East Asia. Our Research is produced for the most part after face to face meetings and conversations with company management to dig deep into the long term vision and strategy of the companies we cover. We seek to deliver investable and actionable themes on sectors and markets across SE Asia, often in collaboration with other Insight Providers across the region, pooling the vast experience of the analysts within the Smartkarma Ecosystem. We also offer bespoke work and tailor made trips for our clients. 

Insights across South East Asia

Equity Bottom-Up

<p><a href="https://www.smartkarma.com/entities/1261" target="_blank" data-smartkarma-citation="entities:1261:1">Consun Pharmaceutical Group (1681 HK)</a> share price fell 8% on the 31st May 2018, while their YTD performance is still +20%, outperforming both <a href="https://www.smartkarma.com/entities/22899" target="_blank" data-smartkarma-citation="entities:22899:1">Hong Kong Hang Seng Index (HSI INDEX)</a>  and <a href="https://www.smartkarma.com/entities/22900" target="_blank" data-smartkarma-citation="entities:22900:1">Hang Seng China Enterprises Index (HSCEI INDEX)</a> by 19%. After a call with the management, the following points were discussed:</p><ol><li>Fall on the share price</li><li>UCG market position</li><li>Guangxi Yulin Plant, Hydrogel Patch, and IPO</li><li>Iron dextran solution for women and children</li><li><p>Valuation and Trade Idea</p></li></ol>

Consun Pharmaceutical Group (1681 HK) share price fell 8% on the 31st May 2018, while their YTD performance is still +20%, outperforming both Hong Kong Hang Seng Index (HSI INDEX)  and Hang Seng China Enterprises Index (HSCEI INDEX) by 19%. After a call with the management, the following points were discussed:Fall on the share priceUCG market positionGuangxi Yulin Plant, Hydrogel Patch, and IPOIron dextran solution for women and childrenValuation and Trade Idea

Consun Pharma: A Call with Management Reveals More Value

China

Jilin Province Huinan Changlong Bio-pharmacy Company Limited manufactures and distributes biochemical medicines in China under the brand names of Changlong and Shendi. The Company also manufactures and distributes Chinese medicines and Western medicines.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jilin Province Huinan H (8049 HK)

Consun Pharma: A Call with Management Reveals More Value

Consun Pharmaceutical Group (1681 HK) share price fell 8% on the 31st May 2018, while their YTD performance is still +20%, outperforming both Hong...

Henry Soediarko

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)